

Leda Dunn Wettre  
 ROBINSON, WETTRE & MILLER LLC  
 One Newark Center, 19th Floor  
 Newark, New Jersey 07102  
 Telephone: (973) 690-5400  
 Facsimile: (973) 466-2760  
 Lwettre@rwmlegal.com

Eric I Abraham  
 Christina L. Saveriano  
 HILL WALLACH LLP  
 202 Carnegie Center  
 Princeton, NJ 08540  
 Telephone: (609) 924-0808  
 Facsimile: (609) 452-8888

*Of Counsel:*  
 William G. Gaede, III  
 Bhanu K. Sadasivan  
 Shane G. Smith  
 Evan Boetticher  
 McDERMOTT WILL & EMERY LLP  
 275 Middlefield Road, Suite 100  
 Menlo Park, CA 94025  
 Telephone: (650) 815-7400  
 Facsimile: (650) 815-7401

*Of Counsel:*  
 Michael J. Gaertner  
 Scott B. Feder  
 Amanda K. Kelly  
 Andy J. Miller  
 LOCKE LORD LLP  
 111 South Wacker Drive  
 Chicago, IL 60606  
 Telephone: (312) 443-0700  
 Facsimile: (312) 443-0336

*Attorneys for Plaintiff Depomed, Inc.*

*Attorneys for Defendant Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited*

RECEIVED

JUN - 9 2014

AT 8:30 M  
 WILLIAM T. WALSH CLERK

**IN THE UNITED STATES DISTRICT COURT  
 FOR THE DISTRICT OF NEW JERSEY**

DEPOMED, INC.,	)	
	)	
Plaintiff,	)	Civil Action No. 3:12-CV-02813 (JAP) TJB
	)	
v.	)	
	)	
ZYDUS PHARMACEUTICALS (USA), INC.,	)	
and CADILA HEALTHCARE LIMITED	)	
	)	
Defendants.	)	
	)	

---

**CONSENT INJUNCTION AND DISMISSAL ORDER**

This action for patent infringement (the "Litigation") has been brought by Plaintiff Depomed, Inc. ("Depomed") against Defendants Zydus Pharmaceuticals (USA), Inc. and Cadila Healthcare Limited (collectively, "Zydus") for alleged infringement of United States

✓ Patent Nos.: 6,635,280; 6,723,340; 6,340,475; 6,488,962; 7,438,927; 7,731,989; 8,192,756; 8,252,332; and 8,333,992 (collectively the “Asserted Patents”). Depomed’s commencement of the Litigation was based on its receipt of notice from Zydus that Zydus had filed Abbreviated New Drug Application (“ANDA”) No. 203934 with the United States Food and Drug Administration (“FDA”) containing a certification pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) directed to the Asserted Patents and seeking approval to market generic versions of Gralise® brand 300 mg and 600 mg gabapentin tablets.

Depomed and Zydus have agreed to enter into a good faith final settlement agreement (the “Settlement and License Agreement”) regarding this Litigation on the expectation and belief that this would eliminate the substantial litigation costs that would otherwise be incurred by Depomed and Zydus during the Litigation, while also serving the public interest by saving judicial resources and avoiding the risks to each of the parties associated with infringement. The Settlement and License Agreement will afford Depomed and Zydus the procompetitive opportunity to more productively use money and other resources that would have been spent in the continued prosecution and defense of this Litigation, to the benefit of the parties and consumers alike, such as by investing more money in pharmaceutical research and development.

Each of Depomed and Zydus acknowledge that the continued prosecution of this Litigation is not in their commercial interests and have consented to entry of this order through a final settlement as reflected herein. The Court, upon the consent and request of Depomed and Zydus, hereby issues the following Order.

Depomed and Zydus now consent to this Consent Injunction and Dismissal Order, and

IT IS HEREBY ORDERED that:

1. Subject matter jurisdiction, personal jurisdiction, and venue are all proper in this Court.
2. In this Litigation, Depomed charged Zydus with infringement of the Asserted Patents in connection with Zydus's submission of ANDA No. 203934 directed to generic tablets containing 300 mg and 600 mg of gabapentin per tablet to the FDA.
3. In response to Depomed's charges of patent infringement, Zydus has alleged certain defenses and counterclaims, including that the Asserted Patents are invalid or not infringed. The Court has not adjudicated Depomed's charges of patent infringement or Zydus's defenses and counterclaims.
4. Zydus, their officers, agents, servants, employees and attorneys, and those persons in active concert or participation with them who receive actual notice of this Order by personal service or otherwise, are hereby enjoined from manufacturing, using, offering to sell or selling within the United States and its territories and possessions, including the Commonwealth of Puerto Rico (the "Territory"), or importing into the Territory, any generic tablet product containing 300 mg or 600 mg of gabapentin per tablet that is the subject of ANDA No. 203934 until such day as may be permitted by the Settlement and License Agreement that the Parties have entered into. Each of Depomed and Zydus each expressly waives any right to appeal or otherwise move for relief from this Consent Injunction and Dismissal Order.
5. Neither this Consent Injunction and Dismissal Order nor the entry of this Consent Injunction and Dismissal Order may be asserted by Depomed against Zydus, and shall have no preclusive effect whatsoever, with respect to any product other than that described in Zydus's ANDA No. 203934 (including any amendments, supplements, or

replacements).

6. Nothing herein prohibits or is intended to prohibit Zydus from maintaining a “Paragraph IV Certification” pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (including as amended or replaced) or pursuant to 21 C.F.R. § 314.94(a)(12) (including as amended or replaced) with respect to the Asserted Patents.

7. All claims, counterclaims and defenses as between Depomed and Zydus are hereby dismissed without prejudice.

8. This Court retains jurisdiction over Depomed and Zydus for purposes of enforcing this Consent Injunction and Dismissal Order.

[THE REST OF THIS PAGE INTENTIONALLY LEFT BLANK]

9. The Clerk of the Court is directed to enter this Consent Injunction and Dismissal Order forthwith.

**IT IS SO STIPULATED.**

By: Leda Dunn Wettre

Leda Dunn Wettre

ROBINSON, WETTRE & MILLER LLC

One Newark Center, 19th Floor

Newark, New Jersey 07102

Telephone: (973) 690-5400

Facsimile: (973) 466-2760

Lwettre@rwmlegal.com

By: Christina Saveriano

Eric I Abraham

Christina L. Saveriano

HILL WALLACH LLP

202 Carnegie Center

Princeton, NJ 08540

Telephone: (609) 924-0808

Facsimile: (609) 452-8888

*Of Counsel:*

William G. Gaede, III

Bhanu K. Sadasivan

Shane G. Smith

Evan Boetticher

MCDERMOTT WILL & EMERY LLP

275 Middlefield Road, Suite 100

Menlo Park, CA 94025

Telephone: (650) 815-7400

Facsimile: (650) 815-7401

*Of Counsel:*

Michael J. Gaertner

Scott B. Feder

Amanda K. Kelly

Andy J. Miller

LOCKE LORD LLP

111 South Wacker Drive

Chicago, IL 60606


Telephone: (312) 443-0700

Facsimile: (312) 443-0336

*Attorneys for Plaintiff Depomed, Inc.*

*Attorneys for Defendant Zydus Pharmaceuticals  
(USA), Inc. and Cadila Healthcare Limited*

SO ORDERED this 9<sup>th</sup> day of June, 2014

  
\_\_\_\_\_  
HONORABLE JOEL A. PISANO  
UNITED STATES DISTRICT JUDGE